Germline BRCA Testing, Tumor BRCA Testing, and HRD Testing: What Is the Difference?

A negative BRCA result does not always settle whether you have an inherited cancer risk or whether your tumor has a DNA repair problem.

The answer depends on which test was performed.

Germline BRCA testing looks for a harmful variant in the DNA you were born with. Tumor BRCA testing looks for BRCA changes in the cancer. HRD testing looks for evidence that the tumor has developed problems with a particular DNA repair pathway.

These tests overlap, but they are not interchangeable. Their differences matter for treatment decisions, genetic counseling, and what relatives should be told.

What the Three Tests Can Tell You

Test	What it examines	What it can help establish	What it cannot establish by itself
Germline BRCA testing	Usually DNA from blood or saliva	Whether a harmful BRCA1 or BRCA2 variant is present in your constitutional DNA, with implications for inherited risk and some treatments	Every genetic change present in the tumor or its overall HRD status
Tumor BRCA testing	DNA from a tumor sample	Whether a BRCA1 or BRCA2 variant is detected in the cancer	Whether that variant was inherited
HRD testing	Tumor features associated with defective homologous recombination repair	A biomarker classification that can guide particular treatment decisions, especially in ovarian cancer	A hereditary diagnosis or a guarantee that treatment will work

“Constitutional DNA” means the DNA present throughout the body, rather than only in the cancer.

The specimen matters, but the test's purpose matters too. A blood draw can collect normal DNA for germline testing or circulating tumor DNA for a cancer-focused test. “It was a blood test” does not tell you which question was answered.

Germline BRCA Testing and Inherited Cancer Risk

BRCA1 and BRCA2 help cells repair damaged DNA. Everyone has these genes. The concern is whether a harmful change, called a pathogenic or likely pathogenic variant, is present.

Germline testing can identify a variant relevant to cancer susceptibility even before someone develops cancer. When cancer is already present, the result may also guide treatment.

The CDC's explanation of hereditary cancer testing describes how personal history, family history, ancestry, and known family variants inform the testing discussion.

Testing may involve a multigene panel rather than BRCA1 and BRCA2 alone. A negative BRCA-only test does not answer whether a harmful variant is present in another cancer susceptibility gene.

What a Positive Germline Result Means for Relatives

A harmful germline BRCA variant can have implications for both the patient and blood relatives.

Each biological child of a person carrying a single harmful BRCA variant has a 50% chance of inheriting that variant. That is a chance of inheriting the variant, not a 50% prediction of developing cancer.

Testing relatives for a known family variant is often called cascade testing. A genetic counselor can help identify which relatives should be offered evaluation and how to share the actual laboratory report.

A tumor result alone should not be used to tell children that they carry an inherited variant.

Why Germline Testing Is Not Always a Once-in-a-Lifetime Event

Your underlying inherited DNA generally does not change, but the available tests and the interpretation of results do.

Someone tested years ago may have had a limited panel or a test that did not assess certain changes. Updated testing may be appropriate when technology, family history, or clinical recommendations have changed.

The National Cancer Institute's genetic testing guidance explains circumstances in which additional testing may be considered after an earlier result.

The useful question is whether the previous test adequately answered today's clinical question.

Tumor BRCA Testing and Treatment Decisions

Tumor testing examines cancer DNA, usually from tissue collected during a biopsy or surgery. BRCA analysis may be part of a broader tumor profile.

A harmful BRCA variant found in the tumor may have been inherited. It may also be somatic, meaning it developed in the cancer rather than being present throughout the body.

A tumor-only report generally cannot distinguish those possibilities conclusively. Some testing programs compare tumor DNA with a normal sample, so it is important to know what the laboratory actually analyzed.

The ASCO guideline on germline and somatic testing in epithelial ovarian cancer recommends germline testing for BRCA1, BRCA2, and other ovarian cancer susceptibility genes. For patients without a harmful germline BRCA finding, it recommends tumor BRCA testing.

The guideline also makes clear that germline testing should not depend on first finding a variant in the tumor.

Tumor tests have technical limits. A negative result does not automatically exclude an inherited variant, and inadequate tissue can prevent a reliable result altogether.

HRD Testing Looks Beyond BRCA

HRD stands for homologous recombination deficiency. Homologous recombination is a pathway that helps repair breaks affecting both strands of DNA.

BRCA1 and BRCA2 are important to that pathway, but BRCA changes are not its only possible source of dysfunction. A tumor can be BRCA-negative and still be classified as HRD-positive.

Many clinical HRD assays combine tumor BRCA findings with measurements of genomic instability. These measurements look for patterns sometimes called genomic scars, changes left behind as the tumor accumulated DNA damage.

That is different from directly observing the tumor's repair machinery working in real time.

A 2026 study of HRD prediction in ovarian cancer explains that genomic scars reflect historical repair problems. A tumor can retain those scars even if its repair capacity later changes.

The test method matters. Different assays use different measurements and thresholds, so scores should not be treated as interchangeable.

HRD testing is especially relevant to certain ovarian cancer maintenance decisions. Its meaning should not be transferred automatically to breast, pancreatic, or prostate cancer.

What BRCA and HRD Results Mean for PARP Inhibitors

PARP inhibitors interfere with DNA repair processes. Certain tumors with BRCA-related or other homologous recombination defects can be particularly vulnerable to these drugs.

A biomarker result is only part of treatment eligibility. The cancer type, stage, prior treatment, response to chemotherapy, previous PARP exposure, and the specific drug all matter.

The 2026 ASCO living guideline on PARP inhibitors in ovarian cancer recommends genetic testing for newly diagnosed advanced epithelial ovarian cancer and HRD tumor testing when BRCA-negative.

It supports particular maintenance approaches after response to platinum-based chemotherapy in patients with BRCA mutations or HRD-positive disease. It does not recommend PARP maintenance for BRCA-nonmutated, HRD-negative ovarian tumors.

That is why an older statement that HRD-negative patients may still receive the same maintenance treatment can be misleading.

Drug labeling matters as well. The current niraparib prescribing information limits its first-line ovarian maintenance indication to HRD-positive disease meeting the label's requirements.

An HRD-positive result does not guarantee a response or make every PARP inhibitor appropriate.

How to Read Results That Do Not Match

Different results can be medically consistent because the tests answer different questions.

Germline BRCA-negative and tumor BRCA-positive. The tumor finding may be somatic. The team should confirm that the germline test adequately assessed the relevant variant before making conclusions about inherited risk.

BRCA-negative and HRD-positive. The assay may have identified genomic instability without detecting a qualifying BRCA variant. This does not, by itself, diagnose an inherited cancer syndrome.

Germline testing negative but family history remains concerning. The result may be uninformative rather than an explanation for the family's cancers. Counseling should consider the genes tested, the test's limitations, and whether a known family variant exists.

HRD testing unsuccessful or inconclusive. This is not the same as HRD-negative. The laboratory may have lacked enough suitable tumor material to classify the sample.

Ask for the actual reports. A chart entry saying only “BRCA negative” can leave essential information unclear.

Insurance and Genetic Consent in New York

Coverage is not identical for hereditary risk testing, tumor profiling, and HRD testing. Ask the ordering office about the specific test, laboratory, authorization requirements, and expected patient cost.

If coverage is denied, obtain the written reason. The New York State external appeal process may apply to qualifying denials, including certain medical-necessity determinations. The available route depends on the plan and the basis for denial.

New York also has specific genetic consent and confidentiality rules. Civil Rights Law 79-l generally requires prior written informed consent for testing within its definition, subject to statutory exceptions, and regulates disclosure of results.

Its requirements should not be assumed to apply identically to every tumor assay. Ask what consent covers, who will receive the results, and whether genetic counseling is available.

When Missed Testing May Raise a Malpractice Question

A missed test or delayed result is not automatically medical malpractice.

A New York claim generally requires a departure from accepted care and an injury caused by that departure. The assessment must use the clinical circumstances and standards applicable at the time.

Potential concerns include a qualifying patient never being offered appropriate testing, a harmful result not being communicated, an inadequate sample being treated as a negative result, or a treatment decision being made without needed findings.

The review must also identify what the omission changed. Was an appropriate treatment delayed or lost? Was indicated risk management omitted? What injury can medical evidence connect to that failure?

A New York cancer malpractice review examines those questions. The existence of a genetic variant alone does not prove that a clinician caused the cancer or mishandled the care.

Discuss Concerns About a Missed or Unexplained Result

Keep copies of the complete genetic and tumor reports, test orders, sample-failure notices, insurance decisions, and messages discussing the findings.

Porter Law Group can review concerns about missed testing, an uncommunicated result, or a delay affecting cancer care.

Call 833-888-LATE, email info@porterlawteam.com, or request a review of your cancer testing concerns.

This article provides general educational information, not medical or legal advice. Discuss testing and treatment with your oncology team and a qualified genetic counselor. Do not postpone medical care while seeking legal advice.

Attorney Advertising. Reading this article or contacting the firm does not create an attorney-client relationship.

Frequently Asked Questions

Does a Negative Tumor BRCA Test Mean I Do Not Need Germline Testing?

No. Tumor testing does not replace an indicated hereditary cancer evaluation. The assays examine different material and have different technical limits. In epithelial ovarian cancer, germline testing is recommended independently of a tumor finding. Ask whether the test you received addressed inherited risk or only the cancer's treatment biomarkers.

Does HRD-Positive Mean I Inherited a BRCA Mutation?

No. An HRD-positive tumor can lack a detectable BRCA variant, and a BRCA variant found in a tumor may be somatic rather than inherited. HRD is a tumor classification used for particular treatment decisions. Hereditary risk requires a separate assessment of germline testing and personal and family history.

Can a Blood Test Be Tumor Testing Rather Than Germline Testing?

Yes. Some blood tests analyze circulating tumor DNA, while others analyze constitutional DNA for hereditary variants. The fact that blood was collected does not establish the test's purpose. Ask for the assay name and report, and confirm whether the laboratory evaluated inherited risk, tumor findings, or both.

Is an Unsuccessful HRD Test the Same as HRD-Negative?

No. An unsuccessful or inconclusive test means the laboratory could not provide a reliable classification. A negative result means the sample was classified under that assay's criteria. Ask whether another tissue sample, additional material, or a different testing approach is appropriate before the result is used for treatment planning.

Does a Positive BRCA Result Guarantee That a PARP Inhibitor Will Work?

No. A qualifying harmful BRCA variant may support treatment eligibility in a specific setting, but it does not guarantee benefit. The cancer type, treatment history, chemotherapy response, drug indication, and safety considerations still matter. A variant of uncertain significance should not be treated as a qualifying harmful variant.